Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of cas 2225868-19-7 123b9 in China, also supports custom service. Welcome to wholesale bulk high quality cas 2225868-19-7 123b9 from our factory. Contact us for more details.
| Product Name | CAS 2225868-19-7 123B9 |
| Description | 123B9 is a potent and selective EphA2 (Ephrin type-A receptor 2) agonist peptide, CAS 2225868-19-7. Its sequence is {2-(3-chloro-4-fluorophenoxy)acetic acid}-Ser-Ala-Tyr-Pro-Asp-Ser-Val-Pro-{Nle}-{Hsr}-Ser-NH₂, a rationally designed modified peptide: the N-terminus is hydrophobically modified with 2-(3-chloro-4-fluorophenoxy)acetic acid (CFPA, an aryloxyacetic acid containing a chloro-fluoro substituted benzene ring), enhancing binding affinity with the receptor hydrophobic pocket; non-natural amino acids such as norleucine (Nle, a non-oxidizable methionine analog) and homoserine (Hsr) are introduced into the peptide chain, improving metabolic stability and receptor selectivity; C-terminal amidation further enhances biological activity and enzymatic resistance. 123B9 selectively binds the ligand-binding domain of the EphA2 tyrosine kinase receptor with a Kd of 4.0 μM, activating downstream signaling pathways of the EphA2 receptor. Notably, 123B9 does not appreciably inhibit the ligand-binding domains of the most closely related EphA3 and EphA4 receptors, demonstrating good subtype selectivity. EphA2 receptor is overexpressed in various malignancies (such as breast, prostate, lung, and ovarian cancers), closely associated with tumor invasion, metastasis, and angiogenesis. As a tumor-homing agent, 123B9 can be used in tumor-targeted drug delivery, tumor imaging probe development, EphA2 signaling pathway research, and anti-tumor therapeutic strategy exploration. |
| Peptide Purity (HPLC, %) | ≥98% |
| Molecular formula | C₅₈H₈₂ClFN₁₂O₂₀ |
| Molecular weight (Da) | 1321.79 |
Product Basic Information Table
| Product Standard English Name | Product Abbreviation / Alias | Function Tags (comma-separated) | Core Structure | Molecular Formula | Exact Mass (Da) | Average MW (Da) | Salt Form | Length (aa) |
| 123B9 | c-Met targeting peptide 123B9; HGF receptor antagonist peptide | Receptor antagonist peptide, anti-metastasis, cell invasion inhibition, tumor targeting, anti-fibrosis | c-Met/HGFR-specific peptide that competitively binds to the extracellular domain of c-Met, blocks HGF-induced receptor activation and downstream signaling, and inhibits tumor cell migration, invasion and angiogenesis | C₅₅H₇₉N₁₅O₁₀ | 1121.61 | ~1122.4 | Acetate | 9 |
Physicochemical Solubility & Storage Parameters
| Product Code | Appearance | Long-term Storage | Short-term Storage | Solution Stability | Solid Powder Stability |
| PEP-12B009 | White powder | Store at -20°C, sealed, dry and protected from light. Aliquot for storage. | Stable for 1 month at 2–8°C in sealed dry condition; stable for shipping at ambient temperature. | Stable for 7 days at 4°C. Acetate salt is freely soluble in water, dilute acetic acid and PBS. Good stability under neutral conditions; conformational change and binding activity loss under strong alkaline conditions. | Stable for 2 years at -20°C, dry and protected from light. |
Functional Description
| Product Code | Frontend Short Summary (for search list display) | Detailed Biological Function Description | Applicable Research Areas (comma-separated) | Targets / Pathways |
| PEP-12B009 | 123B9 c-Met targeting peptide blocks HGF receptor to inhibit tumor invasion & metastasis | 123B9 is a c-Met-specific antagonist peptide that competitively binds to the extracellular ligand-binding domain of c-Met (hepatocyte growth factor receptor). It blocks HGF-induced receptor dimerization and phosphorylation, and inhibits downstream pro-invasive signaling pathways such as PI3K/Akt and MAPK, effectively suppressing tumor cell migration, invasion and angiogenesis. It is an important tool for c-Met pathway research and anti-metastatic drug development. | Tumor invasion & metastasis research, c-Met signaling pathway, anti-cancer drug development, receptor antagonist study, anti-fibrosis research | Hepatocyte growth factor receptor (c-Met/HGFR); competitive HGF antagonism; PI3K/Akt signaling pathway |
Hot Tags: cas 2225868-19-7 123b9, China cas 2225868-19-7 123b9 manufacturers, suppliers, factory, CAS 191936 91 1, CAS 395069 92 8, CAS 997 20 6, drug delivery peptides, NGR peptide, Tetralysine
